600521.SH
华海药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 16.20
−2.53%Year over year
Reported trailing growth
- Revenue
- -9.2%
- EBITDA
- —
- EBIT
- -64.4%
- EPS
- -68.7%
- Free cash flow
- —
- Operating cash flow
- -5.3%
Forward estimates
Based on analyst estimates
- Revenue
- +7.6%
- EBITDA
- +81.9%
- EPS
- +116.2%
Three-year CAGR
- Revenue
- +1.3%
- EBITDA
- -12.4%
- EBIT
- -33.4%
- Net income
- -38.9%
- EPS
- -39.4%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026